Andrew Sinclair, Ph.D., has served on Adicet Bio's board since March 2021. He is a partner at Abingworth LLP, a life-sciences investment group, where he has worked since November 2008 on investments in public and private biotech and pharmaceutical companies.
Before Abingworth he was a senior equity analyst and director at HSBC Global Markets covering the mid-cap pharmaceutical sector, and earlier held biotechnology analyst positions at Credit Suisse and SG Cowen. He received a B.Sc. in Microbiology from King's College London and a Ph.D. in Chemistry and Genetic Engineering, and qualified as a chartered accountant, formerly with KPMG.